ProCE Banner Activity

Key Viral Hepatitis Studies From AASLD 2021

Slideset Download
Conference Coverage
Read expert faculty members’ summaries of HBV, HCV, and hepatitis delta virus (HDV), including data on HBV therapy during pregnancy, outcomes following treatment withdrawal in HBV, progress toward an HBV cure, HDV clinical impact and phase III clinical trial updates, and HCV implementation science and current status of the cascade of care.

Released: November 29, 2021

Expiration: November 28, 2022

No longer available for credit.

Share

Faculty

Nancy Reau

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Stefan Zeuzem

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Gilead Sciences, Inc.

Faculty Disclosure

Primary Author

Nancy Reau, MD

Associate Professor of Medicine
Center for Liver Disease
University of Chicago
Chicago, Illinois

Nancy Reau, MD, has disclosed that she has received funds for research support paid to her institution from AbbVie and Gilead Sciences and consulting fees from AbbVie, Arbutus, Gilead Sciences, Intercept, and Salix.

Stefan Zeuzem, MD

Professor of Medicine
Chief, Department of Medicine
JW Goethe University Hospital
Frankfurt, Germany

Stefan Zeuzem, MD, has disclosed that he has received consulting fees from AbbVie, Gilead Sciences, Intercept, Janssen, Novo Nordisk, and Sobi and fees for non-CME/CE services from AbbVie, Gilead Sciences, and MSD.